ChemicalBook--->CAS DataBase List--->2527805-39-4

2527805-39-4

2527805-39-4 Structure

2527805-39-4 Structure
IdentificationBack Directory
[Name]

1H-1,2,4-Triazole-3-carboxamide, 5-cyclopropyl-1-(2,4-dichlorophenyl)-N-1-piperidinyl-
[CAS]

2527805-39-4
[Synonyms]

CB1-IN-2
1H-1,2,4-Triazole-3-carboxamide, 5-cyclopropyl-1-(2,4-dichlorophenyl)-N-1-piperidinyl-
[Molecular Formula]

C17H19Cl2N5O
[MOL File]

2527805-39-4.mol
[Molecular Weight]

380.27
Chemical PropertiesBack Directory
[density ]

1.55±0.1 g/cm3(Predicted)
[pka]

10.10±0.20(Predicted)
Hazard InformationBack Directory
[Uses]

CB1-IN-2 (Compound 4g) is a selective CB1 inhibitor with an IC50 of 0.644 μM. CB1-IN-2 can penetrates BBB and might cause CNS side effect similar with Rimonabant[1].
[IC 50]

CB1: 0.644 μM (IC50)
[References]

[1] Tsai SE, et al. Chlorotrimethylsilane promoted one-flask heterocyclic synthesis of 1,2,4-triazoles from nitrilimines: Modeling studies and bioactivity evaluation of LH-21 and Rimonabant analogues. Bioorg Chem. 2020 Nov;104:104299. DOI:10.1016/j.bioorg.2020.104299
2527805-39-4 suppliers list
Company Name: TargetMol Chemicals Inc.
Tel: +17819995354 , +17819995354
Website:
Company Name: Tianjin Kailiqi Biotechnology Co., Ltd.  
Tel: 15076683720
Website: http://www.cw-bio.com
Company Name: TargetMol Chemicals Inc.  
Tel: 15002134094
Website: https://www.targetmol.cn/
Tags:2527805-39-4 Related Product Information

  • HomePage | Member Companies | Advertising | Contact us | Previous WebSite | MSDS | CAS Index | CAS DataBase | Privacy | Terms | About Us
  • All products displayed on this website are only for non-medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.
    According to relevant laws and regulations and the regulations of this website, units or individuals who purchase hazardous materials should obtain valid qualifications and qualification conditions.
  • Copyright © 2023 ChemicalBook All rights reserved.